Key facts
- This page summarizes Thomas Adams PhD's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
- 7 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 14 Jun 2021, 16:10.
Thomas Adams PhD - 10 Jun 2021 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)
- Reporting relationship
- Former Director
- Issuer ticker
- CRDF
- Reported as of
- 10 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2021, 16:10:39 UTC
- Prior SEC filing
- 20 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Adams
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas Adams PhD filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 14 Jun 2021.
Change
- Previous filing in this sequence was filed on 20 May 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +272
- Change %
- +0.06%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 272
- Exercise price
- $447.84
- Footnotes
- F1, F2
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +223
- Change %
- +0.05%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 223
- Exercise price
- $7.18
- Footnotes
- F1
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +223
- Change %
- +0.05%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 223
- Exercise price
- $5.18
- Footnotes
- F1
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +530
- Change %
- +0.11%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 530
- Exercise price
- $51.84
- Footnotes
- F1
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +755
- Change %
- +0.16%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 755
- Exercise price
- $21.60
- Footnotes
- F1
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +298,320
- Change %
- +166%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 298,320
- Exercise price
- $2.48
- Footnotes
- F1, F3
CRDF
transaction
Derivative
Stock Options
Other
- Transaction value
- $0
- Shares
- +173,145
- Change %
- +57%
- Price
- $0.000000
- Shares after
- 477,870
- Date
- 10 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 173,145
- Exercise price
- $2.60
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Expiration date of the stock options was extended to June 10, 2023.
Footnote F2
7,338 of the stock options vest immediately. 4,077 of the stock options vest on each of 2/25/2015 and 2016 and 4,076 of the stock options vest on 2/25/2017.
Footnote F3
In connection with the Reporting Person's separation agreement dated December 21, 2020, the Compensation Committee accelerated the vesting of such stock options to December 29, 2020.